Elisigen
PrivateLast Round
Series C
Jan 19, 2026
Est. Valuation
$179M
Total Funding Raised
$78.45M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Elisigen operates in Enterprise Software and is based in Seoul. Its latest recorded funding round was a Series C round in January 2026.
Elisigen is a biotechnology company that develops AAV-based gene therapies to treat retinal and neurological diseases.
Sector
Enterprise Software
Verticals
Workflow Automation, Project Management, Platform-as-a-Service
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Elisigen Comparables
Compare Elisigen with similar companies based on industry and business-model similarity.
No comparables are published for Elisigen. Book a demo to ask about coverage.
Book a demoFor institutional investors. Book with your work email.
Elisigen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 19, 2026 | ||||
| Series B | Jun 3, 2021 | ||||
| Series A | Apr 30, 2019 | ||||
| Seed | Oct 25, 2018 |
For institutional investors. Book with your work email.
Elisigen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Investment | Series B |
| KB Investment | Series C |
| Seven Tree Equity Partners | Series B |
| Ulmus Investment | Series B |
| Premier Partners | Series C |
| NICE F&I | Series C |
| QUAD Investment Management | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 19, 2026
$29M round with participation from NH Investment & Securities and Premier Partners.
- May 21, 2024
Grew 67% QoQ, from 6 to 10 employees.
For institutional investors. Book with your work email.
Elisigen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Elisigen's valuation, stock price, and market status.
Is Elisigen a public or private company?
Elisigen is a private company.
What is the current stock price of Elisigen?
Elisigen is a private company, so its shares have no public market price. Caplight tracks Elisigen's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Elisigen worth (valuation)?
Elisigen's valuation is estimated at $179.0M based on funding round data.
Can I buy Elisigen stock?
Elisigen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Elisigen's last funding round?
Elisigen's most recent funding round was Series C on January 19, 2026.
Who are the main investors in Elisigen?
Key investors in Elisigen include SV Investment, KB Investment, Seven Tree Equity Partners, Ulmus Investment, Premier Partners.
Will Elisigen IPO soon?
No public IPO plans have been announced for Elisigen.
How can I track Elisigen secondary market activity?
Caplight tracks bids, offers, and trades in Elisigen's shares on secondary markets.